Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „zonisamide“
Suchtreffer
Begriffe & Kennungen
Zonisamide Viatris (previously Zonisamide Mylan) · 4.1 Therapeutic indications · 1
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.3 Contraindications · 1
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or to sulfonamides.
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.5 · - CYP3A4 inhibition: Based upon clinical data, known specific and non-specific CYP3A4 inhibitors appear to hav
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.5 · - Enzyme induction: Exposure to zonisamide is lower in epileptic patients receiving CYP3A4-inducing agents suc
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.5 · 9 possible pharmacodynamic interaction (see section 4.4).
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.5 · Carbonic anhydrase inhibitors Zonisamide should be used with caution in adult patients treated concomitantly w
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.5 · Effect of zonisamide on cytochrome P450 enzymes In vitro studies using human liver microsomes show no or littl
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.5 · Oral contraceptives In clinical studies in healthy subjects, steady-state dosing with zonisamide did not affec
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.5 · P-gp substrate An in vitro study shows that zonisamide is a weak inhibitor of P-gp (MDR1) with an IC50 of 267
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.5 · Paediatric population Interaction studies have only been performed in adults.
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.5 · Potential for zonisamide to affect other medicinal products Anti-epileptic medicinal products In epileptic pat
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.5 · Potential medicinal product interactions affecting zonisamide In clinical studies co-administration of lamotri
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.5 · Zonisamide is metabolised partly by CYP3A4 (reductive cleavage), and also by N-acetyl-transferases and conjuga
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.5 · Zonisamide should not be used as co-medication in paediatric patients with other carbonic anhydrase inhibitors
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.8 Undesirable effects · 1
Eintrag öffnenZonisamide Viatris (previously Zonisamide Mylan) · 4.8 · 11 marked decreases in weight of 20% or more was 0.7%.
Eintrag öffnen